Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for Serina Therapeutics (SER) over the last 7 years, with Q3 2025 value amounting to 12.38%.

  • Serina Therapeutics' Return on Capital Employed fell 149100.0% to 12.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.38%, marking a year-over-year decrease of 149100.0%. This contributed to the annual value of 3.11% for FY2024, which is 24400.0% down from last year.
  • Latest data reveals that Serina Therapeutics reported Return on Capital Employed of 12.38% as of Q3 2025, which was down 149100.0% from 5.21% recorded in Q2 2025.
  • Serina Therapeutics' Return on Capital Employed's 5-year high stood at 24.01% during Q1 2021, with a 5-year trough of 12.38% in Q3 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 1.08% (2024), whereas its average is 0.89%.
  • The largest annual percentage gain for Serina Therapeutics' Return on Capital Employed in the last 5 years was 575300bps (2021), contrasted with its biggest fall of -260100bps (2021).
  • Quarter analysis of 5 years shows Serina Therapeutics' Return on Capital Employed stood at 1.28% in 2021, then fell by -27bps to 0.94% in 2022, then plummeted by -136bps to 0.34% in 2023, then tumbled by -961bps to 3.62% in 2024, then crashed by -242bps to 12.38% in 2025.
  • Its Return on Capital Employed was 12.38% in Q3 2025, compared to 5.21% in Q2 2025 and 4.7% in Q1 2025.